Study of ATEZOLIZUMAB Combination CARBOPLATIN + PACLITAXEL + BEVACIZUMAB in EGRF Mutation or ALK Translocation NSCLC

Condition:   Non-small Cell Lung Cancer Interventions:   Drug: Atezolizumab(Tecentriq);   Drug: Pemetrexed;   Drug: Bevacizumab;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Carboplatin or cisplatin Sponsor:   Samsung Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials